Morgan Stanley
IMCR icon

Morgan Stanley’s Immunocore IMCR Stock Holding History

Morgan Stanley’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96M Sell
187,850
-135,756
-42% -$4.02M ﹤0.01% 4108
2026
Q1 		$9.76M Buy
323,606
+36,481
+13% +$1.18M ﹤0.01% 3586
2025
Q4 		$9.97M Buy
287,125
+17,921
+7% +$633K ﹤0.01% 3620
2025
Q3 		$9.78M Buy
269,204
+31,325
+13% +$1.06M ﹤0.01% 3572
2025
Q2 		$7.46M Buy
237,879
+64,018
+37% +$1.99M ﹤0.01% 3719
2025
Q1 		$5.16M Buy
173,861
+43,220
+33% +$1.3M ﹤0.01% 3898
2024
Q4 		$3.85M Sell
130,641
-274,184
-68% -$8.67M ﹤0.01% 4214
2024
Q3 		$12.6M Sell
404,825
-464,039
-53% -$16.9M ﹤0.01% 3248
2024
Q2 		$29.4M Buy
868,864
+67,590
+8% +$3.45M ﹤0.01% 2251
2024
Q1 		$52.1M Sell
801,274
-115,789
-13% -$7.95M ﹤0.01% 1722
2023
Q4 		$62.7M Sell
917,063
-44,025
-5% -$2.29M 0.01% 1503
2023
Q3 		$49.9M Buy
961,088
+148,466
+18% +$8.79M 0.01% 1583
2023
Q2 		$48.7M Buy
812,622
+16,131
+2% +$921K ﹤0.01% 1592
2023
Q1 		$39.4M Buy
796,491
+441,769
+125% +$24.8M ﹤0.01% 1765
2022
Q4 		$20.2M Buy
354,722
+204,972
+137% +$11.5M ﹤0.01% 2333
2022
Q3 		$7.03M Buy
149,750
+126,403
+541% +$6.02M ﹤0.01% 3342
2022
Q2 		$871K Buy
23,347
+20,995
+893% +$682K ﹤0.01% 5099
2022
Q1 		$70K Buy
2,352
+947
+67% +$23.9K ﹤0.01% 6523
2021
Q4 		$48K Sell
1,405
-916
-39% -$33.2K ﹤0.01% 6832
2021
Q3 		$86K Buy
2,321
+2,301
+11,505% +$77.7K ﹤0.01% 6455
2021
Q2 		$1K Sell
20
-15,187
-100% -$586K ﹤0.01% 7614
2021
Q1 		$648K Buy
+15,207
New +$677K ﹤0.01% 5010

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Morgan Stanley's IMCR Position: Q2 2026 in Review

Morgan Stanley reduced its Immunocore (IMCR) stake by 42% in Q2 2026, selling an estimated $4.02M and leaving 187,850 shares worth $5.96M. The position accounts for ﹤0.01% of the portfolio, ranked #4108.

Morgan Stanley first reported a position in IMCR in Q1 2021 and has held it in 22 quarters since. The position peaked at $62.7M in Q4 2023. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Morgan Stanley held 187,850 shares of Immunocore worth $5.96M as of Q2 2026.
  • Morgan Stanley sold 135,756 Immunocore shares in Q2 2026, an estimated $4.02M.
  • Immunocore made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4108 holding.
  • Morgan Stanley first reported a position in Immunocore in Q1 2021 and has held it in 22 quarters since.
  • Morgan Stanley's Immunocore position peaked at $62.7M in Q4 2023.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.